Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Tlr4 signaling" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof
InactiveUS20100239589A1Treat orMetabolism disorderMicrobiological testing/measurementImmune signalingInsulin resistance
The present invention relates generally to the Tlr4 signaling pathway specifically in the hematopoietic system and its contribution to insulin resistance of liver and adipose tissue. The hematopoietic component expressing Tlr4 is a principle propagator of immune signaling and results in insulin resistance. Furthermore, disclosed herein are methods and compositions for treating or preventing disorders associated with insulin resistance using a Tlr4 antagonist.
Owner:SALK INST FOR BIOLOGICAL STUDIES +1
Selective Inhibition of TLR4 Signaling
InactiveUS20100069297A1Enough disruptionCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsHomologous sequenceBiological activation
Blocking peptides comprised of the 14 amino acids that correspond to the sequences of the BB-loops of the four known TIR domain-containing adapter proteins (i.e. MyD88, TRAM, TIRAP, and TRIF) and homologous sequences of four TLRs (TLR2, TLR4, TLR1, and TLR6) are described. Adapter BB loop peptides disrupted TLR4, but not TLR2 signaling. TLR2 and TLR4 blocking peptides inhibited TLR4- and TLR2-mediated activation of ERK and cytokine induction, however, these peptides did not inhibit activation of p38. These peptides can be used to treat or prevent an immune or inflammatory response associated with a condition related to TLR4 signaling.
Owner:MARYLAND UNIV OF
Substituted cyclohexenes
InactiveUS20090022706A1Significant clinical effectAvoid signalingBiocidePeptide/protein ingredientsCyclohexeneMedicinal chemistry
Disclosed herein are substituted cyclohexene TLR4 signaling pathway modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Owner:AUSPEX PHARMA INC
Research method for applying TLR4 to curing acute kidney injury caused by sepsis
InactiveCN108517334AProtectiveMicrobiological testing/measurementFermentationWestern blotStudy methods
The invention provides a research method for applying TLR4 to curing acute kidney injury caused by sepsis, and relates to the technical field of medical treatment. The method comprises the steps of mouse septic AKI model building; animal modelling judgement; specimen collection; normal and septic AKI mouse kidney cell primary culture; TLR4 determination by means of immunohistochemistry (SP method)and semi-quantitation; Real-time PCR detection of expression change of VEGF, sFLT-1, TNF-alpha and TLR4mRNA of septic AKI mouse primary kidney cells; detection of protein level expression change of VEGF, sFLT-1, TNF-alpha and TLR4 of septic AKI mouse primary kidney cells through a Western-blot method; constructing VEGF gene eukaryotic expression plasmids and optimal silence mouse VEGF gene ShRNAexpression plasmids; experimental grouping; TLR4 cell treatment; index detection; verifying TLR4 target regulation on VEGR expression; searching for protein in interaction with the VEGF; discussing molecule mechanisms which is possibly involved in TLRs signal path adjustment of the VEGF. The method speculates that the VEGF and the TLR4 signal path are in interaction for regulating the acute kidneyinjury caused by sepsis and play a part in protection.
Owner:邦世(苏州)生物医药科技有限公司
Exosome and preparing method and application thereof
ActiveCN109777770AAnti-inflammatoryPromote healingNervous disorderUnknown materialsPostoperative cognitive dysfunctionApoptosis
The invention discloses an exosome and a preparing method and application thereof, and relates to the field of exosome medicines. In order to solve the problem of postoperative cognition dysfunction,mesenchymal stem cells are separated out of cornu cervi tissue; after culturing, a cell culture solution is collected, and the exosome from cornu cervi mesenchymal stem cells are extracted through separation. It is proved that CPB rat nerve function deficit and oxidative stress response can be relived, a protection effect is realized for CPB rat nerve cell apoptosis and CPB rat POCD can be relieved through a TLR2 / TLR4 signal channel. The exosome can be used for preparing medicines for improving or treating the cognition dysfunction.
Owner:INST OF SPECIAL ANIMAL & PLANT SCI OF CAAS
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
ActiveUS20120238610A1Mitigating and preventing complicationBiocideSenses disorderDendritic cellFactor ii
Owner:OHIO UNIV
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
Owner:NOVIMMUNE
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
This invention relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of Toll-like Receptor 4 (TLR4) ligands and other biomarkers. The invention also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder associated with elevated levels of TLR4 ligands and other biomarkers using agents that interfere with or otherwise antagonize TLR4 signaling, including neutralizing anti-TLR4 antibodies.
Owner:NOVIMMUNE
New target using curcumin to inhibit hepatic cancers and application
InactiveCN108324702APromote apoptosisPrevent proliferationMicrobiological testing/measurementKetone active ingredientsStatistical analysisWestern blot
The invention belongs to the technical field of medical treatment, and discloses a new target using curcumin to inhibit DAMP (damage associated molecular pattern) molecule HSP70 and TLR4 signals to inhibit hepatic cancers and application. By establishing a cell culture and cell heat stress model, the statistical analysis is performed by CCK-8 test, scratch experiment, Transwell transfer experiment, cell cycle analysis by a flow cytometry, cell withering analysis by the flow cytometry, Western blot analysis, enzyme linked immunosorbent assay and other methods. Proofed by the statistical analysis result, the application has the advantages that the level of DAMP molecule HSP700 outside the cell and the expression of TLR4 protein are obviously increased by the heat stress, and the expression of DAMP molecule HSP700 inside the cell is obviously reduced; the proliferation, invasion and transfer of human hepatoma cell line HepG2 cells are inhibited by the curcumin, the cell withering is promoted, the cell is blocked at the S period, and the heat-stress level of the DAMP molecule HSP70 (eHSP70) outside the HepG2 cell is obviously reduced; after the curcumin is removed, the eHSP70 is increased again.
Owner:任碧琼
Application of Jasurolignoside in production of medicine for treating and/or preventing lung injuries
ActiveCN111388492AImprove survival rateImprove respiratory functionOrganic active ingredientsAntiinfectivesPharmaceutical drugProinflammatory cytokine
The invention discloses application of Jasurolignoside in production of a medicine for treating and / or preventing lung injuries of mammals, including humans. A structural formula of the Jasurolignoside is shown in a formula (I) as shown in the description. According to application of the Jasurolignoside in production of the medicine for treating and / or preventing the lung injuries of the mammals,including the humans, the medicine has a certain effect of preventing the lung injuries, inhibits release of proinflammatory cytokines of the lungs, and inhibits TLR4 signal channels.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Use of toll-like receptor 4 agonist crx-675 against pulmonary fibrosis
InactiveCN102258527AImprove lung functionReduce mortalityOrganic active ingredientsRespiratory disorderHydroxyprolineMortality rate
The invention discloses an application of a stimulating agent CRX-675 of a Toll-like receiver 4 in resisting pulmonary fibrosis. By systematic study, the inventor discovers that a pulmonary fibrosis model is formed by injecting bleomycin (3U / Kg) into the trachea of C57BL / 6 mouse, after 7 days from model forming, CRX-675(10mg / kg / day) is injected into the abdominal cavity to the 21st day; by the histopathology and biochemical detection and other methods, when a TLR4 signal channel is activated, the death rate of the mouse injected with the bleomycin can be obviously reduced; when the TLR4 signal channel is activated, the inflammations and injuries of the lung induced by the bleomycin are obviously reduced, the pulmonary fibrosis caused by the bleomycin is reduced, the collagen deposition in the lung, the content of hydroxyproline and the expression of alpha-SMA are reduced, and the function of the lung of the mouse by pulmonary fibrosis is improved.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Application of ginsenoside GRh2 in preparing toxoplasma gondii resisting compound preparation and medicine thereof
ActiveCN108888628APrevent proliferationProlong survival timeOrganic active ingredientsAntiparasitic agentsInflammatory factorsInfected cell
The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.
Owner:YANBIAN UNIV
Application of traditional Chinese medicine composition for treating depression in regulating immune inflammatory reaction
InactiveCN109602884ADefinite curative effectSignificant antidepressant effectAntipyreticAnalgesicsAMERICAN GINSENG ROOTCurcuma aromatica
The present invention relates to the technical field of medicine and particularly relates to an application of a traditional Chinese medicine composition for treating depression in regulating an immune inflammatory reaction and an intervention mechanism and the application of the traditional Chinese medicine composition for treating the depression, and the traditional Chinese medicine compositioncomprises radix curcumae, spina date seeds, American ginseng and fructus schizandrae. The traditional Chinese medicine composition significantly reverses up-regulated expression levels of TLR4 and MyD88 proteins in hippocampus induced by chronic restraint stress under reversal functions of interventions on chronic restraint stress-induced rat weight loss, decreased sweet water preference index, decreased horizontal motor scores and vertical motor scores, etc., and at the same time widely regulates immunoinflammatory activation mediated by a pattern recognition receptor TLR4 signaling pathway.
Owner:SHANTOU CITY SIJI PHARMA
Application of a kind of ginsenoside grh2 in the preparation of anti-toxoplasma compound preparation and its medicine
ActiveCN108888628BPrevent proliferationProlong survival timeOrganic active ingredientsAntiparasitic agentsInfected cellInflammatory factors
The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.
Owner:YANBIAN UNIV
A kind of traditional Chinese medicine preparation and its preparation and application
ActiveCN106063903BInhibit aggregationImprove solubilityDispersion deliveryRespiratory disorderLung alveolusPulmonary interstitium
The invention discloses a traditional Chinese medicine preparation and its preparation and application. The preparation is made from the following raw materials by weight: 20-30 parts of Astragalus root, 20-30 parts of Nansha ginseng, 20-30 parts of Beisha ginseng, and 10-30 parts of Lily Radix. 20 servings, 5-15 servings of dendrobium, 10-20 servings of aster, 10-20 servings of loquat leaves, 10-20 servings of bitter almond, 10-20 servings of Bai Bu, and 10-20 servings of angelica. It has the functions of clearing the lungs, relieving cough and relieving asthma, nourishing qi, nourishing yin and promoting blood circulation. After taking, the drug can directly act on the lesions of radiation pneumonia, inhibit the exudation of inflammatory cells in the alveolar wall, pulmonary interstitial congestion, hemorrhage, edema and alveolar structure damage, reduce the TLR4 signaling pathway signaling molecule protein and local lung. The expression of cytokines in tissue-related cells can reduce the inflammatory response of the lungs and achieve the purpose of delaying or treating radiation pneumonitis.
Owner:HANGZHOU NORMAL UNIVERSITY
Application of transferrin in preparing immunosuppressant medicines
PendingCN111166872AInhibition recognitionInhibition of activationPeptide/protein ingredientsAntipyreticInflammatory factorsAntigen
The invention provides application of transferrin in preparing immunosuppressant medicines and belongs to the technical field of biomedicines. Transferrin is capable of targeting at a co-receptor monocyte surface antigen CD14 of a TLR4 (toll-like receptor 4), then recognition of lipopolysaccharide (LPS) and CD14 is inhibited, LPS induced TLR4 signal path activation is also inhibited, LPS induced inflammatory factors are inhibited, LPS induced plasma inflammatory factors TNF-alpha, IL-6, IL-1beta and IFN-beta are inhibited, and LPS induced liver tissue damage and cell apoptosis can be alleviated. The transferrin has a very remarkable effect in inhibiting inflammation induced by bacterium products. The transferrin is capable of inhibiting inflammation reactions induced by bacterium productsand in addition, has the potential of preparing immunosuppressant medicines.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Use of jasurolignoside in the preparation of medicines for treating and/or preventing lung injury
ActiveCN111388492BImprove survival rateImprove respiratory functionOrganic active ingredientsAntiinfectivesPulmonary InjuryPharmaceutical drug
The invention discloses the use of Jasurolignoside in the preparation of medicines for treating and / or preventing lung injury in mammals including humans. The structural formula of Jasurolignoside is formula (I): the invention has a certain protective effect on lung injury and inhibits lung inflammation Sexual cytokine release and inhibition of TLR4 signaling pathway.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Application method of traditional Chinese medicine composition and clinical model establishing method
The invention discloses an application method of a traditional Chinese medicine composition and a clinical model establishment method in the field of medical pharmacy, and aims to overcome the difficulty in reduction of a theoretical system of a treatment mechanism of the traditional Chinese medicine composition for supporting the traditional Chinese medicine composition in the prior art, namely treatment based on syndrome differentiation of holistic concept. According to the defects which cannot be explained by current scientific biological pharmacy and chemical pharmacy, the composition is applied to a receptor TLR4 signal channel and a brain signal transduction channel radiation range of channel radiation to generate a model group, a baseline serves as a boundary of the model group, and difference data between treatment endpoint remission rate and endpoint response rate groups are filled into parameters in the model group. According to the technical scheme, the composition is applied to divided receptors, compared with analysis of effective components of a mixture by existing drug avoidance; meanwhile, the drug effect principle is explained through bioengineering, and the therapeutic dose of the optimal area is determined.
Owner:SHANTOU CITY SIJI PHARMA
Cationic liposome containing DHA and HMGB1-silent siRNA, preparation method and application of cationic liposome
ActiveCN110123807AOrganic active ingredientsGenetic material ingredientsImmunologic disordersAutoimmune disease
The invention provides a cationic liposome containing dihydroartemisinin (DHA) and HMGB1-silent siRNA, and a preparation method and an application of the cationic liposome, thereby constructing a novel drug delivery carrier. The cationic liposome not only can realize high drug loading and co-encapsulation of multiple drugs, but also can avoid liver first pass effect and improve pharmacokinetic characteristics; and the HMGB1-silent siRNA and the DHA are constructed in the same drug delivery carrier, and multiple targets act on the TLR4 signal axis, and thus a synergistic effect on LN treatmentis played, and a creative research method for treating autoimmune diseases is provided.
Owner:ZHEJIANG PHARMA COLLEGE
Application of turnip acidic polysaccharide BRAP-2
The invention provides an application of turnip acidic polysaccharide BRAP-2. The turnip acidic polysaccharide BRAP-2 is used for treating mouse Lewis lung cancer by activating a TLR4 signal path. Theturnip acidic polysaccharide BRAP-2 plays an important role in treating the mouse Lewis lung cancer, has a wide clinical application prospect, and provides a new target for clinical development of drugs for treating lung cancer.
Owner:XINJIANG MEDICAL UNIV
Compounds and treatments that enhance enteric nervous system function
PendingUS20220079935A1Avoid lostSignal degradationOrganic active ingredientsPeptide/protein ingredientsDiseaseNervous system
The present inventive concepts, compositions and methods are show that the enteric glial serve to restrain the exaggerated TLR4 signaling that occurs in the premature intestinal epithelium via the release of BDNF, and that necrotizing enterocolitis (NEC) develops due to a loss of enteric glia. Compositions and methods of treatment of NEC and related enteric disease in prenatal, premature and neonatal subjects using compositions heretofore unknown for inhibition of NEC or activation of enteric glia are also provided.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Rabdosia japonica polysaccharide as well as preparation method and application thereof
The invention relates to rabdosia japonica polysaccharide as well as a preparation method and application thereof. The structure of the rabdosia japonica polysaccharide is shown in the specification, and the rabdosia japonica polysaccharide is mainly composed of arabinose, rhamnose, xylose, glucose and galactose. Experiments prove that the rabdosia japonica polysaccharide has the effects of treating inflammation-related diseases, especially chronic atrophic gastritis and acute lung injury by inhibiting an Ana-1 cell LPS induced TLR4 signal channel, so that the rabdosia japonica polysaccharide has the potential of being developed into the medicine for treating the inflammation-related diseases.
Owner:SHANGAI PHARMA GRP CO LTD +1
Application of stimulating agent CRX-675 of Toll-like receiver in resisting pulmonary fibrosis
InactiveCN102258527BImprove lung functionReduce mortalityOrganic active ingredientsRespiratory disorderHydroxyprolineMortality rate
The invention discloses the application of Toll-like receptor 4 agonist CRX-675 in resisting pulmonary fibrosis. The inventor found through systematic research that for C57BL / 6 mice, the pulmonary fibrosis model was caused by intratracheal injection of bleomycin (3U / Kg). After 7 days of modeling, intraperitoneal injection of CRX-675 (10mg / kg / day) to the 21st day; through histopathological and biochemical detection methods, it was found that activating the TLR4 signaling pathway can significantly reduce the mortality of bleomycin-infused mice; activating the TLR4 signaling pathway can significantly reduce the lung inflammation induced by bleomycin and damage, reduce bleomycin-induced pulmonary fibrosis, including reducing lung collagen deposition, hydroxyproline content and expression of α-SMA, and improve lung function in mice with pulmonary fibrosis.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Application of reagent for inhibiting pyroptosis of platelets in preparation of medicine for preventing and/or treating sepsis
ActiveCN114569722AProven treatment effectMammal material medical ingredientsDisease diagnosisTherapeutic effectBlood plasma
The invention discloses application of a reagent for inhibiting pyroptosis of platelets in preparation of a medicine for preventing and / or treating sepsis, and the sepsis is severe sepsis or septic shock. In the invention, the inventor finds out the close relevance between severe sepsis and pyroptosis of platelets for the first time, reveals the pathological process of GSDMD-dependent pyroptosis of platelets, and finds that pyroptosis of platelets is generated based on induction of abnormally increased S100A8 / A9 in plasma through up-regulation of a TLR4 signal channel. Therefore, a theoretical basis is provided for development of targeted treatment targets of severe sepsis. Moreover, specific GSDMD knockout platelets and TLR4 knockout platelets are successfully constructed, the treatment effect of the specific GSDMD knockout platelets and the specific TLR4 knockout platelets on severe sepsis is proved through platelet replacement or infusion and other modes, and a new treatment strategy is provided for excessive inflammatory response of severe sepsis and platelet infusion.
Owner:GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
Toll-like receptor 4 (TLR4) inhibitors and use thereof
PendingUS20210196717A1Organic active ingredientsNervous disorderSignalling pathwaysCardio vascular disease
Peptides, peptidomimetics and small molecules, collectively referred to as “decoy peptides”, are provided, which interfere with binding to a TIR domain of a toll-like receptor 4 (TLR4), and inhibit a TLR4-induced signaling pathway. These decoy peptides may be useful for treating diseases associated with induction of TLR4 signaling pathway such as a disease or disorder secondary to a cardiovascular disease, sepsis or an inflammatory disease.
Owner:BAR ILAN UNIV +1
Peptide therapeutics for autoimmune and inflammatory diseases
PendingCN114502570APolypeptide with localisation/targeting motifPeptide/protein ingredientsAutoimmune conditionTLR signaling pathway
The present invention relates to a peptide that inhibits a Toll-like receptor (TLR) signaling pathway. More specifically, the present invention relates to: a peptide that strongly binds to a TIR-containing molecule to inhibit the TLR, in particular the TLR4 signaling pathway; a fusion peptide in which a cell penetrating peptide is conjugated to the peptide; a TLR4 antagonist comprising the peptide or the fusion peptide; and a composition for preventing or treating an autoimmune disease or an inflammatory disease, the composition comprising the peptide or the fusion peptide. According to the present invention, the peptide has an inhibitory effect on a plurality of TLR signaling pathways including TLR4, blocks a MyD88-dependent TLR4 pathway and a TRIF-dependent TLR4 pathway, and has a significant disease-alleviating effect on rheumatoid arthritis, psoriasis, systemic lupus erythematosus and non-alcoholic steatohepatitis, therefore, the compound can be effectively used as a therapeutic agent for immune-related diseases and inflammatory diseases in which negative regulation of TLR is required.
Owner:GENESEN CO LTD
TLR4-based protective action mechanism for acute liver injury model caused by sepsis
InactiveCN113243337AImprove acute liver injuryBlock inflammatory responseMicrobiological testing/measurementNucleic acid vectorDiseaseMolecular biology
The invention discloses a TLR4-based protective action mechanism for an acute liver injury model caused by sepsis. The TLR4-based protective action mechanism comprises the following steps: step 1, constructing a mouse Sepsis model and grouping; step 2, constructing an miR-214 expression lentiviral vector; step 3, performing miR-214 intervention; step 4, collecting and detecting a sample; and step 5, carrying out statistical processing. By discussing the influence of regulation and control over the expression of the miR-214 on mice and whether the overexpression of the miR-214 can inhibit a TLR4 signal transduction pathway or not, the inflammatory reaction is blocked, and the acute liver injury caused by sepsis is improved; and influence of regulation and control over the expression of the miR-214 on the mice is researched on the basis of the TLR4 signal transduction pathway, a reference is provided for clinical treatment of the disease, and the TLR4-based protective action mechanism has important significance on clinical treatment of sepsis.
Owner:国药葛洲坝中心医院
Novel TLR4 antagonist
ActiveCN107922460AEfficient use ofImprove the activation effectPeptide/protein ingredientsAntipyreticInterleukin 6Autoimmune disease
The present invention relates to a peptide for inhibiting a TLR4 signaling pathway, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. More specifically, the present invention relates to a peptide which binds to a TLR4 / MD2 composite to inhibit the secretion of interleukin-6 (IL-6), NO, and ROS, and the activation ofNF[kappa]B and MAPKs, a TLR4 antagonist comprising the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. The peptide according to the present invention has an excellent effect of inhibiting the secretion of interleukin-6 (IL-6), NO, and ROS, and the activation of NF[kappa]B and MAPKs by inhibiting a TLR4 signaling pathway induced by a liphopolysaccharide (LPS), and thus can be favorably used as a composition for preventing or treating autoimmune diseases and inflammatory diseases occurring by the TLR4 signaling pathway.
Owner:GENESEN CO LTD
Novel tlr4 antagonists
ActiveCN107922460BEfficient use ofImprove the activation effectPeptide/protein ingredientsAntipyreticAutoimmune conditionWhite blood cell
Owner:GENESEN CO LTD
Mimic polypeptides of myeloid differentiation protein-2 and application thereof
The invention provides a group of novel polypeptides derived from myeloid differentiation protein-2 (MD-2), which comprises an amino acid sequence of SEQ1 (SEQ1: CHGHDDDYSFCFSFEGILFPKGHYR) or a variant or a fragment thereof. The actual detection results show that the polypeptides can inhibit a TLR4 signal path which is triggered by LPS from being activated, inhibit excessive inflammatory response induced by in vitro-in vivo LPS, and improve survival rate of mouse damaged by endotoxin, thus being capable to be used for preparing a curative drug for endotoxin related inflammation including pyaemia.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com